Key result
Compound 20B (gylongiposide I) isolated from Gynostemma pentaphyllum extract stimulated insulin secretion from rat pancreatic islets in a glucose-dependent manner, showing activity at high (16.7 mM) but not low (3.3 mM) glucose concentrations.
Why the study?
Does gylongiposide I stimulate glucose-dependent insulin secretion in isolated pancreatic islets from diabetic and non-diabetic rats?
Does gylongiposide I stimulate glucose-dependent insulin secretion in isolated pancreatic islets from diabetic and non-diabetic rats?
p-value: p=<0.01
Gylongiposide I, isolated from Gynostemma pentaphyllum, demonstrates glucose-dependent insulinogenic effects in vitro, suggesting potential as a novel anti-diabetic therapeutic.
Hypothesis-generating for gylongiposide I as a glucose-dependent secretagogue; requires validation in diabetic models before any clinical consideration.
The global prevalence of type 2 diabetes is increasing rapidly; consequently there is great need for new and novel therapeutic options. Gynostemma pentaphyllum (GP) is a traditional medicinal plant, mainly present in Southeast Asian countries, that has been reported to exert antidiabetic effects, by stimulating insulin secretion. The specific compound responsible for this effect is however as yet unidentified. Screening for discovery and identification of bioactive compounds of an herbal GP extract, was performed in isolated pancreatic islets from spontaneously diabetic Goto-Kakizaki (GK) rats, a model of type 2 diabetes, and from non-diabetic control Wistar rats. From this herbal extract 27 dammarane-type saponins, including two novel compounds, were isolated and their structure was elucidated by mass spectrometry and NMR spectroscopy. One of the dammarane-type triterpenoid showed a glucose-dependent insulin secretion activity. This compound, gylongiposide I, displays unique abilities to stimulate insulin release at high glucose levels (16.7 mM), but limited effects at a low glucose concentration (3.3 mM). Further studies on this compound, also in vivo, are warranted with the aim of developing a novel anti-diabetic therapeutic with glucose-dependent insulinogenic effect.
No takes yet. Share an insight, caveat, or question.
Lundqvist et al. (2019) studied Type 2 diabetes (animal model) (n=33). Gylongiposide I (Compound 20B from Gynostemma pentaphyllum) vs. Control (0 µg/ml) was evaluated on Insulin secretion at low (3.3 mM) and high (16.7 mM) glucose concentrations (p=<0.01). Compound 20B (gylongiposide I) isolated from Gynostemma pentaphyllum extract stimulated insulin secretion from rat pancreatic islets in a glucose-dependent manner, showing activity at high (16.7 mM) but not low (3.3 mM) glucose concentrations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: